Treatment of cardiovascular diseases using anti-human gpvi antibodies
AssigneeActicor Biotech
InventorsGilles AVENARD, Yannick PLETAN, Jean-Marie GROUIN, Sophie BINAY, Elie TOLEDANO, Andrea COMENDUCCI
Life of this patent
Estimating the term…
Abstract
An inhibitor of GPVI signaling pathway, in particular an isolated humanized protein binding to human Glycoprotein VI (hGPVI), for treating a GPVI-related condition in a subject in need thereof, in particular an acute ischemic stroke, including the administration of the inhibitor GPVI signaling pathway, in particular the anti-human glycoprotein VI antibody or fragment thereof, to a human patient in need thereof.
Claims17
1-16. (canceled)
A method for treating a GPVI-related condition in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an isolated humanized protein binding to human Glycoprotein VI (hGPVI), wherein said subject presents at least one of the following conditions:
- said subject is affected with a moderate to severe GPVI-related condition,
- said subject is of 65 years of age or older, and/or
- said subject is undergoing or has undergone thrombectomy and thrombolysis,
- preferably wherein said GPVI-related condition is a stroke, more preferably an acute ischemic stroke.
A method for decreasing the degree of disability or dependence following a GPVI-related condition, such as a stroke, in a subject, comprising administering to said subject a therapeutically effective amount of an isolated humanized protein binding to human Glycoprotein VI (hGPVI), preferably the method decreasing the risk of having a modified Rankin Scale (mRS) score measured 90 days after the administration of the isolated humanized protein equal to or greater than 4 or increasing the probability of having a mRS score measured 90 days after the administration of the isolated humanized protein equal to or lower than 3.
A method for preventing the occurrence of intracranial hemorrhages in a subject affected with a GPVI-related condition, comprising administering to said subject a therapeutically effective amount of an isolated humanized protein binding to human Glycoprotein VI (hGPVI), wherein preferably said GPVI-related condition is a stroke, more preferably an acute ischemic stroke.
A method for decreasing the risk of death in a subject affected with a GPVI-related condition, preferably for decreasing the risk of death within a time period of 20 days after the onset of the GPVI-related condition, preferably within a time period of 10 days after the onset of the GPVI-related condition, and even more preferably the risk of death within a time period of 5 days after the onset of the GPVI-related condition, the method comprising administering to said subject a therapeutically effective amount of an isolated humanized protein binding to human Glycoprotein VI (hGPVI), wherein preferably said GPVI-related condition is a stroke, more preferably an acute ischemic stroke.
Dependencies are inferred from the claim text.